Tehran University of Medical Sciences The Research in Heart Yield and Translational Medicine (RHYTHM) 3115-7270 20 3 2025 11 02 170 172 Masih Tajdini Tehran Heart Center, Tehran University Heart Center, Tehran, Iran. 2025 10 28 2025 10 31 Introduction : Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have evolved from glucose-lowering medications for diabetes into foundational cardiometabolic therapies, supported by robust evidence of cardiovascular protection from major clinical trials.1 Their dual capacity to reduce hyperglycemia and promote substantial weight loss is particularly relevant in regions like Iran and the Middle East, where the prevalence of obesity (∼25%), overweight (∼60%), and diabetes (∼10%) is rising rapidly; regional diabetes prevalence is projected to increase by more than 80% by 2050. By enhancing glucose-dependent insulin secretion, suppressing glucagon release and appetite, lowering blood pressure, improving lipid profiles, and exerting anti-inflammatory vascular effects, GLP-1 RAs such as liraglutide, semaglutide, and dulaglutide offer a comprehensive strategy for mitigating the intertwined risks of metabolic and cardiovascular disease. https://jthc.tums.ac.ir/index.php/jthc/article/view/2380 https://jthc.tums.ac.ir/index.php/jthc/article/download/2380/1225